Statins In Intracerbral Hemorrhage (SATURN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03936361|
Recruitment Status : Recruiting
First Posted : May 3, 2019
Last Update Posted : July 23, 2021
|Condition or disease||Intervention/treatment||Phase|
|Intracerebral Hemorrhage||Drug: Statins||Phase 3|
SATURN is a multi-center, pragmatic, prospective, randomized, open-label, and blinded end-point assessment (PROBE) clinical trial. A total of 1,456 patients presenting within 7 days of a spontaneous lobar ICH while taking statins will be randomized to one of two treatment strategies: discontinuation vs. continuation of statin therapy (using the same agent and dose that they were using at ICH onset). Participating subjects will undergo baseline testing for APOE genotype and will be followed for 24 months to assess for the occurrence of recurrent symptomatic ICH or major adverse cerebro-/cardio-vascular events (MACCE) during the follow-up period.
Recruitment will take place at ~ 140 sites coordinated through the NIH/NINDS StrokeNet and the Canadian Stroke Consortium.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1456 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Participants will be randomized at 1:1 ratio to either continue the same statin drug and dosage that they are taking at the time of ICH onset or to discontinue it for up to 24 months after ICH. No placebo will be prescribed for those randomized to discontinue statins.|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS|
|Actual Study Start Date :||June 10, 2020|
|Estimated Primary Completion Date :||June 30, 2026|
|Estimated Study Completion Date :||December 31, 2026|
Active Comparator: Statin
The same statin agent and dose that subjects were using at the time of ICH onset.
Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
Other Name: HMG CoA
No Intervention: No-statin
Subjects will discontinue the statin agent that they were taking at the time of ICH onset. No placebo will be prescribed for these subjects.
- Recurrent symptomatic ICH [ Time Frame: within 24 months ]
- Major Adverse Cerebro- and Cardio-Vascular Events [ Time Frame: Within 24 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03936361
|Contact: Magdy Selim, MD, PhDemail@example.com|
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Magdy Selim, MD, PhD|